180 related articles for article (PubMed ID: 18434184)
21. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Zhu AX
Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy for hepatocellular carcinoma].
Okusaka T; Ueno H; Ikeda M
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2122-8. PubMed ID: 15628756
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
25. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
Finn RS
Clin Cancer Res; 2010 Jan; 16(2):390-7. PubMed ID: 20068087
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
Kudo M
Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
28. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
29. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
Berasain C; Castillo J; Prieto J; Avila MA
Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
32. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
33. Systemic therapy for hepatocellular carcinoma.
Thomas MB
Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
[TBL] [Abstract][Full Text] [Related]
34. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of hepatocellular carcinoma and molecular therapies.
Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapy for advanced hepatocellular carcinoma: a review.
Nowak AK; Chow PK; Findlay M
Eur J Cancer; 2004 Jul; 40(10):1474-84. PubMed ID: 15196530
[TBL] [Abstract][Full Text] [Related]
39. Systemic chemotherapy of hepatocellular carcinoma--Korean experience.
Lee HC
Oncology; 2008; 75 Suppl 1():114-8. PubMed ID: 19092280
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Ramanathan RK; Belani CP; Singh DA; Tanaka M; Lenz HJ; Yen Y; Kindler HL; Iqbal S; Longmate J; Mack PC; Lurje G; Gandour-Edwards R; Dancey J; Gandara DR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):777-83. PubMed ID: 19169683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
